Phaseline

Companies › SynOx Therapeutics

SynOx Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Sep 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Emactuzumab
Macrophage colony stimulating factor receptor inhibitor
CSF1RPhase 3TGCTSep 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05417789EmactuzumabPhase 3TGCTOncologySep 2030

Targets

CSF1R (1)

Companies with the same targets

Daiichi Sankyo Syndax Pharmaceuticals Incyte Turning Point Therapeutics Deciphera Pharmaceuticals Merck KGaA Gossamer Bio USA Abbisko Therapeutics Qurient Xynomic Pharmaceuticals

Companies built like this

NingBo Junyan Hongshi Biosciences Taizhou Hanzhong biomedical InSightec NovoCure Summit Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.